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EPC-1/PEDF (early population doubling level cDNA-1/retinal pigmented epithelium-derived factor) is a single-copy,
quiescence-speciﬁc gene that is transcribed into a 1.5 kb mRNA and then translated into a 50 kDa secreted protein
that is a potent inhibitor of angiogenesis. EPC-1 expression has been detected in a number of cultured cell lines,
including lung and skin ﬁbroblasts, retinal pigmented epithelial cells, and endometrial stromal ﬁbroblasts.
Furthermore, its expression has been shown to decline during replicative aging of these cells in culture. In this
report, we describe our examination of the age-related changes in EPC-1 expression in situ in skin sections from
donors of different ages. EPC-1 mRNA is detected primarily in the dermal layer of the skin and its expression
declines with increasing donor age. This decline is statistically signiﬁcant between young (less than 31 years old)
and middle-aged (between 30 and 60 years old) donors, with the decline becoming less dramatic at older ages. This
age-related decline in the expression of an angiogenic inhibitor contributes to the imbalance of angiogenic
modulators that is observed during aging. In fact, this decline may reﬂect a compensatory change to help reverse
the decline of angiogenesis marked by reduced abundance of microvessels. This downregulation of an angio-
genesis inhibitor may, in turn, play a critical role in the development of diseases caused by abnormal vascularization.
The potential role of the age-associated decline in EPC-1 expression in tissue remodeling and in the development
of skin diseases with excessive angiogenesis may provide new insights into disease prevention.
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Aging is a deteriorative process marked by a functional
decline, a decreased capacity for adaptive responsiveness,
an increased susceptibility to cancer and other diseases,
and an increased probability of death. Contributing to the
global ‘‘functional decline’’ are multiple changes in gene
expression patterns, which have been characterized in a
variety of tissues and cell culture models (Cristofalo et al,
1998b).
The EPC-1 (early population doubling level cDNA-1) gene
is one gene whose expression has been shown to decline
dramatically during cellular aging in normal human lung and
skin fibroblast lines (Doggett et al, 1992; Pignolo et al, 1993;
Tresini et al, 1999; Pignolo et al, 2003). EPC-1 is expressed
in several growth-arrested (G0) non-transformed cell lines,
including human lung, skin, and endometrial stromal
fibroblasts, vascular smooth muscle cells, retinal-pigmen-
ted epithelial cells, and T lymphocytes (Pignolo et al, 1995;
Tombran-Tink et al, 1996). In addition, EPC-1 mRNA
expression has been detected in vivo in a broad range of
fetal and adult tissues including the ovary, testis, lung, liver,
skeletal muscle, and small intestine (Tombran-Tink et al,
1996).
The EPC-1 gene product is a 50 kDa secreted protein
that was shown to be identical to retinal pigmented
epithelium-derived factor (PEDF) and the mouse homolog,
caspin (collagen-associated serpin; Tombran-Tink et al,
1991; Doggett et al, 1992; Pignolo et al, 1993; Shirozu et al,
1996; Kozaki et al, 1998). Since EPC-1 is secreted by G0
fibroblasts, we have suggested that EPC-1 plays a role in
the maintenance of or entry into G0 (Pignolo et al, 2003).
This is supported by the fact that cells exhibiting a
senescent or transformed phenotype, which are therefore
incapable of entering a G0 growth-arrested state, produce
little or no EPC-1 mRNA (our unpublished results; Pignolo
et al, 2003). Other functional studies have shown that EPC-1/
PEDF/caspin (EPC-1) can induce neurite-like outgrowth
(Becerra et al, 1993; Steele et al, 1993; Seigel et al, 1994;
Stratikos et al, 1996) and protects against glutamate- and
hydrogen peroxide-induced toxicity in retinal neurons and
cerebellar granule cells (Taniwaki et al, 1995; Taniwaki et al,
1997; Cao et al, 1999; DeCoster et al, 1999; Cao et al,
2001). The latter effect has been reported to be due to
protection from apoptosis through the activation of NF-kB
(Araki et al, 1998; Yabe et al, 2001).
As a means of examining the functional role of EPC-1/
PEDF, Dawson et al (1999) have shown that EPC-1/PEDF is
a powerful inhibitor of endothelial cell migration in vitro and
neovascularization in the eye in vivo, suggesting its role as a
major inhibitor of angiogenesis. Additional reports have
suggested that loss of EPC-1 expression in the eye, as a
Abbreviations: EPC-1, early population doubling level cDNA-1;
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result of either increasing age (Tombran-Tink et al, 1995) or
disease, may play a role in the development of the wet form
of macular degeneration or diabetic retinopathies (Ohno-
Matsui et al, 2001; Rasmussen et al, 2001; Spranger et al,
2001; Holekamp et al, 2002; Ogata et al, 2002; Semkova
et al, 2002; Yamagishi et al, 2002). These reports suggest
that the balance between levels of EPC-1 and pro-angio-
genic agents such as vascular endothelial cell growth factor
(VEGF) in the eye is important for preventing certain debilitat-
ing retinal diseases that are caused by neovascularization.
As an inhibitor of angiogenesis, EPC-1 has been
suggested to regulate the vasculature and mass of the
pancreas and prostate (Doll et al, 2003). Lack of EPC-1/
PEDF in knockout mice resulted in increased stromal blood
vessels and epithelial hyperplasia. We believe that this will
also be true in the skin, which contains a rich source of
stromal fibroblasts that produce EPC-1 and microcapillaries
that can respond to angiogenic activators. Thus, if EPC-1
expression declines with age in tissues as predicted by cell
culture models, an environment would be created that is
more permissive for cancer growth and metastasis.
Control of the angiogenic environment is more complex
than accounting for the abundance of just one modulator,
EPC-1. Although we predict an increase in vascularity due
to a reduction in EPC-1 expression, angiogenesis in general
has been shown to be delayed or impaired as a function of
increasing age (Yamaura and Matsuzawa, 1980; Pili et al,
1994; Rivard et al, 1999; Swift et al, 1999; Sadoun and
Reed, 2003). Some of these studies, however, are con-
founded by the use of pathological models such as creating
ischemia in the hind limbs of rabbits (Rivard et al, 1999) and
examining excisional wounds in mice (Swift et al, 1999). A
recent report by Sadoun and Reed (2003) characterized the
delayed angiogenesis in healthy old mice compared with
young mice by examining the neovascular response in
implanted polyvinyl alcohol sponges. The only drawback to
this model is that it might be considered an injury or wound
response. This group showed a decline in the abundance of
pro-angiogenic molecules VEGF and transforming growth
factor (TGF)—b1 and an increase in the angiogenic inhibitor
thrombospondin-2 (TSP-2). Furthermore, there was a
decline in collagen abundance. All of this contributed to
approximately a 40% reduction in capillary density without
changing microvessel morphology and basement mem-
brane composition.
Expression of the EPC-1 gene in vivo as a function of age
in humans has not yet been evaluated. The purpose of this
study was to determine if the decline of EPC-1 expression
observed during replicative senescence of normal fibro-
blasts occurs in situ in the skin of donors of different ages.
Here, we demonstrate that EPC-1 mRNA is detected in the
dermal layer of the skin and that it exhibits an age-
associated decline in expression. The largest significant
decline occurs between young and middle-aged donors,
suggesting that reduction in EPC-1 expression may be one
of the earliest aging events that disturbs the delicate
homeostatic balance of angiogenic modulators in the tissue
microenvironment. We also show that the EPC-1 protein is
localized to the sub-epidermal region of the skin, suggest-
ing a possible role as a contributor to a protective barrier
against abnormal (for example, sun-induced) skin angio-
genesis (Bielenberg et al, 1998). Finally, we evaluated the
expression of other known angiogenic modulators to obtain
an overall picture of the angiogenic environment in the skin
during human aging. Our results are consistent with the
previously observed age-associated decline of EPC-1
expression in replicative senescence, and suggest that
EPC-1 may play an important role in tissue homeostasis
and contribute to the understanding of the angiogenic
balance during aging.
Results
EPC-1 mRNA expression in the skin We have shown
previously that the abundance of EPC-1 mRNA and protein
is dramatically lower in late passage cultured WI38 human
lung fibroblasts than in early passage cultures (Doggett
et al, 1992; Pignolo et al, 1993, 2003). This was also true of
skin fibroblast cultures derived from donors of different
ages (Tresini et al, 1999). As an extension of that study, we
explored the idea that expression of EPC-1 would be
detected in the skin and that loss of EPC-1 expression
during cellular aging would be reflected in vivo in the skin as
a function of donor age. We examined normal skin sections
for EPC-1 mRNA expression using in situ hybridization with
anti-sense and sense strand RNA probes to determine
specific and non-specific hybridization, respectively. Our
results show that the majority of EPC-1 mRNA expression
was detected in the dermal layer of the skin whereas,
consistent with our in vitro data (Pignolo et al, 1995),
keratinocytes in the epidermis expressed very little EPC-1
mRNA (Fig 1A and B). This result was observed regardless
of the donor age and is consistent with the fact that
fibroblasts, one of the main producers of EPC-1, are the
major cell type in the dermis (Sauer and Hall, 1996).
EPC-1 mRNA expression in the dermis as a function of
age In order to determine if EPC-1 expression declines as
a function of donor age, we examined multiple skin sec-
tions from donors ranging in age from 14 to 82 y
old. Representative sections from two young and two old
donors are shown in Fig 2. Although we do see variability
in tissue sections, the results clearly show that there is
much more hybridization (i.e., grains representing EPC-1
Figure1
EPC-1 mRNA expression is detected in the dermal layer of the
skin. Representative dermal sections from an 18-y-old donor after
in situ hybridization using an anti-sense (A) or sense (B) strand EPC-1
in vitro-transcribed probe, autoradiography, and staining with hema-
toxylin and eosin. The above are representative digital images taken on
a Zeiss microscope. The majority of the hybridization is detected in the
dermis (D) rather than the epidermis (E). Scale bar¼50 mm.
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mRNA) in young donors than in old donors. To quantify the
relative abundance of EPC-1 mRNA in the dermis of each
donor, we used a grain counting program to determine the
percentage of the total dermal area analyzed that reflected
the area covered by grains. The relative abundance of
EPC-1 mRNA detected in the dermis exhibited a signifi-
cant downward trend with increasing donor age (Fig 3).
Furthermore, group analyses showed that EPC-1 mRNA
levels were approximately 3–4-fold higher in young donors
(p30 y old) than in middle-aged (31–60 y old; ANOVA,
Tukey HSD unequal n, p¼0.0018) or old donors (460 years
old; ANOVA, Tukey HSD unequal n, p¼0.00038) (data not
shown). In order to determine if this observation was due to
a reduction in the expression per cell or to a decline in the
number of cells per measured area that express EPC-1
mRNA, the cell number per dermal area (cell density) was
also enumerated. Analysis of 3–6 images per slide showed
that as a function of donor age, there is no significant
difference in the cell density in the dermal area immediately
adjacent to the epidermis (Fig 4A). Previous reports have
shown a decrease in the total number of cells in the dermis
of abdominal skin (Andrew et al, 1964) and a decrease in
average skin thickness as measured in the radial aspect of
the forearm (Black, 1969). Our results may be different from
these reports due to the small area in which we determined
cell density and the close proximity to the epidermal border.
In order to account for the slight differences in cell
density per section, we calculated the average grain density
per cell (Fig 4B). These results show that in addition to
reduced grain density per tissue area, middle-aged (M) and
older (O) individuals show a significant reduction in the grain
density per cell compared with young (Y) donors (M,
p¼0.013 and O, p¼0.0026, ANOVA, LSD test). These
results in combination with the previously published find-
ings, which show an inverse relationship between EPC-1
mRNA expression and the in vitro age of the fibroblasts in
culture (Pignolo et al, 1993), suggest that the fibroblasts in
the skin of older individuals in situ exhibit characteristics of
older (but not senescent) fibroblasts in culture.
EPC-1 protein abundance in the skin as a function of
age EPC-1 mRNA is expressed primarily in the dermis. At
least in vitro, however, EPC-1 is a secreted protein (Pignolo
et al, 2003), and its putative receptor has not been fully
Figure 2
EPC-1 mRNA expression in dermal
sections of young and old donors.
Representative dermal sections from
young and old donors after in situ
hybridization using an EPC-1 in vitro-
transcribed probe as described. The
epidermal (E) and dermal (D) layers of
the skin are indicated. The above are
representative areas from the samples
examined. Scale bar¼50 mm.
Figure3
EPC-1 mRNA expression declines with increasing donor age.
In situ hybridization was used to determine EPC-1 mRNA expression in
skin sections from donors of different ages. The average grain density
per dermal area was determined for each donor. Donors within a given
experiment were normalized to the lowest donor. A power regression
line is shown (n¼ 31, r¼ 0.63, and p¼ 0.000216 as determined by the
Pearson-Product Moment).
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characterized. Only binding properties of EPC-1 to a
potential binding protein in the neural retina and on specific
neurons have been elucidated (Alberdi et al, 1999, 2003;
Aymerich et al, 2001; Bilak et al, 2002). Therefore, it was
important to establish the tissue distribution of the protein
itself. For this, we examined multiple skin sections by
immunofluorescence for the location of the EPC-1 protein.
Since EPC-1 is a secreted protein, we expected to detect
the protein in a gradient radiating from dermal fibroblasts.
Although we do see some staining in the dermal extra-
cellular matrix, our results showed that the bulk of the
protein accumulated in the sub-epidermal region as
indicated by the bracket (Fig 5). In co-staining experiments,
we also examined the tissues for the presence of heparan
sulfate proteoglycan (green fluorescence), which is a major
component of basement membranes and identifies the
dermal–epidermal border. It is clear from Fig 5B (identical to
Fig 5A without the DAPI staining) that the bulk of the EPC-1
protein is just below the basement membrane. Although
there is some variability, our results also suggested that
there was less accumulated EPC-1 protein in older donors
compared with young individuals (Figs 5A and C are 22 and
24 y old, respectively, and E and F are 68 and 74 y old,
respectively). This expression pattern suggests that EPC-1
may be playing a role as a barrier protein as described for
thrombospondin (TSP)-1 and -2 (Wight et al, 1985; Detmar
2000). The potential barrier function of EPC-1 would help
prevent endothelial cell migration out of the vascularized
dermal layer of the skin.
The angiogenic environment in the skin Angiogenesis is
a complex balance of modulators that can stimulate or
inhibit new blood vessel growth in a given tissue. We
additionally evaluated some of these modulators and
microvessel density (MVD) counts to determine how EPC-
1 abundance may contribute to the larger picture of the
angiogenic environment in the skin. We examined the tissue
sections by immunofluorescence so that we can overlay
images to show DAPI staining and multiple proteins. In Fig 6
we show the localization of TSP-1, a potent inhibitor of
angiogenesis. There is generally a greater deposition of
TSP-1 in the extracellular matrix (dermis) of older donors (68
and 74 y old) than in younger donors (22 and 24 y old). We
also examined TSP-2 expression and see a similar increase
in older donors (data not shown) as has been shown by
others (Sadoun and Reed, 2003).
In contrast to the inhibitors, stimulators of new blood
vessel growth trigger angiogenesis and VEGF is the most
potent mitogen for endothelial cells both in vivo and in vitro.
Under conditions that trigger a vascular response (ischemia
or PVA sponges), others have shown that the expression of
VEGF is decreased in tissue from old animals. We examined
VEGF expression by immunostaining in multiple normal skin
sections from young and old donors and show (Fig 7) that
expression is detected in the epidermis of the skin. This is
consistent with previous observations that detected VEGF
mRNA and protein expression in normal keratinocytes in
the epidermis, but not the dermis (Weninger et al, 1996;
Kishimoto et al, 2000). Although some donors show strong
VEGF staining, however, others show little staining. This is
also consistent with the transgenic mouse model using the
VEGF promoter driving green fluorescent protein (GFP),
which shows occasional GFP staining in the unstimulated
epidermis (Kishimoto et al, 2000). Our analyses of young
and old donors show no consistent age difference as shown
with the two young and two old donors in this figure. We
attribute this result to the fact that we are examining the
angiogenic environment in normal tissue, rather than skin
that has been triggered to undergo neovascularization.
Finally, we examined MVD in skin sections as a function
of age (young vs. old). Using an antibody to the endothelial
cell marker CD31, we visualized microvessels in the dermis
and counted the number per field in multiple sections from
each donor examined (Fig 8A). Skin sections from old
donors showed a significantly decreased vessel density.
We also show CD31 staining (green fluorescence with 
indicating stained microvessels in the dermis) in random
fields of three young and three old donors (Fig 8B). Although
we predicted that the decline in expression of the EPC-1
angiogenic inhibitor would lead to an increase in dermal
microvessels, our results are consistent with the age-related
decline in MVD as reported in the literature (Yamaura and
Matsuzawa, 1980; Pili et al, 1994; Sadoun and Reed, 2003).
These results point to the complexity of the angiogenic
environment and that there is a complicated balance of
multiple stimulators and inhibitors. Although there is a
decline in blood vessel density with increasing age and in
some cases an increase in microvessels that result under
Figure 4
EPC-1 mRNA expression as a function of cell number. Following
in situ hybridization, the cell number was determined in the dermal area
of each analyzed image (A). Relative abundance of EPC-1 mRNA was
then determined as a function of cell number (B). Young: p30 y old;
middle-aged: between 30 and 60 y old; and old: 460 y old. Data are
expressed as mean  SD of six independent experiments. Reduction
of relative EPC-1 mRNA abundance compared with young donors,
p¼ 0.013 and p¼0.0026.
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Figure 5
EPC-1 protein accumulates in the
sub-epidermal layer of the epider-
mis and abundance is reduced in
old donors. Skin sections from young
(A–D) and old (E,F) donors were proces-
sed by immunofluorescence to deter-
mine EPC-1 protein localization (Cy3, red
fluorescence), which accumulates in the
sub-epidermal region (brackets). All sec-
tions were also co-stained for heparan
sulfate proteoglycan (HSP), which is
detected with an FITC-labeled second-
ary antibody (green fluorescence in B).
HSPs are the major component of base-
ment membranes and are detected at
the dermal–epidermal border and in
blood vessels (arrows). All images (ex-
cept B) are overlaid with the DAPI stain
(blue fluorescence) image to visualize
the nuclei of all the cells in the tissue. A
representative negative control is shown
(D, same donor as C). Donors: 22 y old
(A, B), 24 y old (C, D), 68 y old (E) and
74 y old (F). These are representative
images from young and old donors. The
epidermal (E) and dermal (D) layers of
the skin are indicated. Scale bar¼
100 mm.
Figure6
Age-associated expression of throm-
bospondin-1 (TSP-1). Skin sections
from young and old donors were pro-
cessed by immunofluorescence to deter-
mine TSP-1 accumulation (FITC). DAPI
images were overlaid to identify the
nuclei of all cells. The epidermal (E) and
dermal (D) layers of the skin are indi-
cated. The donors’ ages are indicated
and these are representative images
from young and old donors. Scale bar¼
100 mm.
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pathological conditions, angiogenesis is not completely
absent in elderly people. We suggest that the decline in
EPC-1 expression helps to balance or reverse the age-
related decline in angiogenesis.
Discussion
EPC-1/PEDF expression has been shown to decline during
replicative aging in cell culture models (Doggett et al, 1992;
Pignolo et al, 1993, 2003; Tombran-Tink et al, 1995; Li et al,
1999; Palmieri et al, 1999; Tresini et al, 1999). There has not
been a study, however, to determine if EPC-1 expression
declines as a function of age in vivo. In a previous report,
Tresini et al (1999) showed that, regardless of donor age,
skin fibroblast lines derived from donors of different ages
(young adults, 17–33 y old and old adults, 78–94 y old)
exhibited an in vitro age-dependent decline in EPC-1 mRNA
expression. No correlation, however, was observed be-
tween EPC-1 mRNA abundance and donor age when
examined at approximately 50%–60% lifespan completed.
One interpretation of this result is that down-regulation of
EPC-1 mRNA abundance is not a biomarker of aging in vivo,
but a senescence-specific change in gene expression
linked to the replicative age of the cells in culture. An
alternative explanation is that the established dermal
fibroblast cultures are not a true representation of the age
of the donor since the resultant fibroblast culture is highly
selected for an outgrowth of the most robust (or youthful)
cells from the skin biopsy. In fact, when the health status
and biopsy conditions are controlled, the replicative lifespan
of fibroblast lines derived from adult skin does not correlate
with donor age (Cristofalo et al, 1998a), suggesting that they
do not represent a realistic picture of gene expression in
vivo. Therefore, it is not surprising that there is no difference
in EPC-1 mRNA abundance between skin fibroblast lines
derived from young and old donors at the same in vitro age.
In order to obtain an accurate representation of EPC-1
expression as a function of donor age, here we examined
skin sections in situ and demonstrated for the first time that
EPC-1 mRNA abundance declines in the dermal layer of the
skin during aging in vivo. Our results show that the largest
Figure 7
Age-associated expression of VEGF.
Skin sections from young and old
donors were processed by immunofluor-
escence to determine VEGF accumula-
tion. DAPI images were overlaid to
identify the nuclei of all cells. Donors:
24 y old (A), 27 y old (B), 68 y old (C) and
74 y old (D and E). A negative control
is shown for Cy3 staining in E. The
epidermal (E) and dermal (D) layers of
the skin are indicated. These are repre-
sentative images from young and old
donors. Scale bar¼100 mm.
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drop in abundance is between young and middle-aged
donors and only a small but not statistically significant
additional drop occurs between middle-aged and old
donors. This trajectory of decline is reflected in the best-fit
power regression line displayed in Fig 3. In contrast, EPC-1
mRNA abundance in senescent cultures in vitro exhibits a
gradual decline during the lifespan of the cells (Tresini et al,
1999). The apparent difference in the trajectory of the age-
associated decline in relative EPC-1 mRNA abundance
between the cell culture model and the tissue may be the
Figure 8
Microvessel density. Skin sections
from young and old donors were pro-
cessed by immunofluorescence to de-
termine CD31 to identify endothelial
cells in the dermis and stained with
DAPI to identify nuclei of all cells in
the tissue sections. Microvessels were
enumerated in five to eight sections per
donor and the average number per
section is shown in A (po0.005, Stu-
dent’s t test, Excel). Representative
images of the CD31 staining (green
fluorescence) in three random young
(B–D) and old (F–H) donors are indi-
cated. Donors: 24 y old (B), 24 y old (C),
27 y old (D), 68 y old (E) and 74 y old (F),
and 78 y old (G).  indicates microves-
sels stained with CD31. Scale bar¼
100 mm.
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result of the selection for the ‘‘youngest’’ cells that occurs in
the process of establishing cultures. Nonetheless, the
general decline observed during the replicative lifespan of
cells in culture is recapitulated in aging dermal tissue.
One alternative explanation for the age-related decline in
EPC-1 mRNA abundance in the dermis is sun damage
rather than aging per se. Most of the tissues that were
examined were from the arm, face, back, or leg, all of which
are from sun-exposed areas. Photodamage increases with
age and at this point it is not clear if the decrease in
expression is due solely to aging or to sun-exposure. Since
we have examined, however, only a few tissues from non-
sun-exposed areas, which also show a decline in EPC-1
mRNA abundance, on-going studies are focused on
deciphering the effects of sun-exposure on EPC-1 expres-
sion.
Given that EPC-1 has been shown to be an inhibitor of
angiogenesis, we suggest that the loss of EPC-1 mRNA
expression in middle-aged individuals is an early event that
begins to disturb the homeostatic balance between various
angiogenic modulators. In turn, this leads to the establish-
ment of an environment that is permissive for neovascular-
ization and perhaps tumor growth via angiogenesis. Our
results may contribute to a better understanding of the role
of EPC-1 in this process.
Interestingly, our results also show that, although EPC-1
mRNA is detected in the dermal layer of the skin, the
secreted EPC-1 protein accumulates in the sub-epidermal
region of the skin. In light of the robust anti-angiogenic
activity of EPC-1, and the fact that the dermis supports a
rich vasculature consisting of capillaries, arterioles, venules,
and lymph capillaries (Okun et al, 1988), EPC-1 may
contribute to the formation of a barrier between the skin
surface (epidermis) and the dermal layer of the skin. This
barrier would prevent the migration of dermal microvascular
cells into the epidermis. A similar hypothesis was proposed
for the anti-angiogenic molecules thrombospondin (TSP)-1
and -2, which are deposited in the basement membrane
area of the skin (Wight et al, 1985; Detmar, 2000). In both
cases, these molecules probably contribute to the barrier
function that blocks blood vessel ingrowth from the
vascularized dermis into the epidermis (Detmar, 2000).
If EPC-1 contributes similarly to barrier function at this
interface but declines with increasing age, this suggests
that there would be an increase in vascular dysplasias and
an increase in diseases that result from abnormal blood
vessel growth. In fact, it is well documented that vascular
dysplasias, such as senile angiomata, cherry angiomatas,
de Morgan spots, angiokeratomas, purpura, palor, venous
lake formation, and telangiectasias, are observed in virtually
all individuals over the age of 70 (Ryan, 1969; Montagna and
Carlisle, 1979; Balin and Lin, 1989; Tsuchida, 1993). Despite
these numerous cutaneous disorders in the elderly, how-
ever, it is generally accepted that angiogenesis is delayed or
impaired during aging (Yamaura and Matsuzawa, 1980; Pili
et al, 1994; Sadoun and Reed, 2003). This points to the fact
that the triggering of angiogenesis is complex and relies on
the balance of many inhibitory and stimulatory molecules.
Whereas our studies have focused on the age-related
decline in the expression of EPC-1, an inhibitor, there is
also an increase in the abundance of other inhibitors, the
thrombospondins and at least in some cases a decline in
VEGF expression (Rivard et al, 1999; Sadoun and Reed,
2003). This gives the impression that many of these
modulators become imbalanced during aging. We suggest
that the loss of EPC-1 expression may reflect a compensa-
tory change that helps to restore the balance that is
disturbed by the changing concentrations and responses
of other modulators in older human donors and animal
models. In so doing, we suggest that this helps establish a
pro-angiogenic environment with numerous cutaneous
vascular diseases, and perhaps tumor growth and metas-
tasis, developing in the elderly. Of interest is that the
microvascular diseases are likely to result from capillary
proliferation and dilation at focal points. This is consistent
with our overall hypothesis that EPC-1 plays a role in
blocking capillary proliferation in young individuals, whereas
in the elderly there is a decline in the production of EPC-1 in
a mosaic fashion, thus resulting in age-associated cuta-
neous vascular dysplasias.
Materials and Methods
Plasmids and preparation of RNA probes The full-length PEDF
cDNA gene (kindly provided J. Tombran-Tink) and the truncated
fragment (797–1489 bp; PEDFD50) were cloned into the pBluescript
plasmid (pBS; Stratagene; La Jolla, California). The full-length
clone was linearized with XhoI to generate an anti-sense probe at
the 30-end of PEDF using T3 RNA polymerase. The PEDFD50 clone
was linearized with EcoRI to generate the sense strand probe with
T7 RNA polymerase. Sense and anti-sense RNA probes were
generated from the linearized templates by using an in vitro
transcription kit (Promega; Madison, Wisconsin) and the probes
were labeled with [35S]-UTP (Amersham Biosciences; Piscataway,
New Jersey). The radioactively labeled RNA probes were purified
by NucTrap probe purification columns according to the manu-
facturer’s instructions (Stratagene).
Tissue sections Burows triangles of normal skin were obtained
during surgical repair of defects following Mohs micrographic
surgery (sun-exposed) or during the harvesting of skin grafts (non
sun-exposed) to repair defects following cancer removal. Indivi-
duals ranged in age from 14 to 82 years old and samples were
categorized as young (p30 years old, n¼ 11), middle-aged (31–60
years old, n¼ 10), and old (460 years old, n¼ 14). The use of
human skin sections in this study was approved by the Main Line
Hospitals (MLH) Institutional Review Board and performed in
accordance with the Declaration of Helsinki Guidelines and with
the MLH federal-wide assurance. Immediately following resection,
the tissue was flash frozen and placed in OCT embedding
compound. Samples from the frozen tissue blocks were cut into
5 mm sections, mounted on clean Snowcoat glass slides, and
stored at 801C in the presence of Dri-Rite.
In situ Hybridization The tissue sections were briefly air-dried
(15–20 min) and fixed in 4% paraformaldehyde in PBS (phosphate-
buffered saline), pH 7.4 (all solutions were made with 0.1% diethyl
pyrocarbonate-treated water). The fixed tissue sections were
acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine
(pH 8.0) for 10 min, rinsed in 2  SSC (0.3 M sodium chloride,
0.03 M sodium citrate), de-hydrated through a graded series of
ethanols, and then air-dried. The hybridization solution consisted of
200 mL of the 35S-labeled RNA probe (8  107 cpm of the probe in
nuclease-free water containing 50 mM DTT (dithiothreotol) and
2.5 mg salmon sperm DNA) and 800 mL of the hybridization buffer
(62.5% formamide, 12.5% dextran sulfate, 0.25 M NaCl, 1.25 
Denhardt’s solution, 12.5 mM Tris, pH 7.5, 1.25 mM EDTA, pH 8.0
in nuclease-free water). A 50 mL aliquot of the hybridization solution
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was applied to each tissue section, covered with a coverslip,
and incubated for 3.5 h at 551C in a humidified chamber. After
hybridization, the sections were washed at room temperature (RT)
in 4  SSC with gentle agitation (40 min). Coverslips were gently
removed and sections were washed 5 more times in 4X SSC (5 min
each, RT). This was followed by treatment with RNase A to remove
the unhybridized probe (20 mg/mL RNase A in 0.5 M NaCl, 10 mM
Tris, pH 7.5, 1 mM EDTA; 30 min at 371C). The tissue sections were
then washed (RT) in two changes of 2  SSC, one wash 1  SSC,
and one wash of 0.5  SSC, all containing 1 mM DTT. This was
followed by a high stringency wash in 0.1  SSC containing 1 mM
DTT (551C, 30 min). Following five dips in 0.1  SSC (RT), the
sections were then dehydrated sequentially in 50%, 75%, and
95% ethanol (in 1 mM DTT and 0.1  SSC) for 3 min each, and
finally three changes of 100% ethanol (3 min). Air-dried slides were
exposed to Amersham Hyperfilm for 1–4 d at 41C to determine
optimal emulsion exposure time based on negative controls and a
14C standard slide.
Autoradiography was performed by dipping the slides in Kodak
NTB2 nuclear track emulsion that was diluted 1:1 with sterile
distilled water (Eastman Kodak Company, Rochester, NY). After
exposure in the dark at 41C (3 d in emulsion for every day on film),
the slides were developed in Kodak D-19 developer for 5 min, fixed
in Kodak fixer for 5 min, rinsed extensively in water, and stained
with hematoxylin and eosin. To evaluate the specificity of the 35S-
labeled anti-sense EPC-1 probes to the tissue sections, control
experiments were performed using a 35S-labeled sense EPC-1
probe separately for each sample. The hybridized and stained
skin sections were examined by light microscopy using a Zeiss
microscope and images were recorded using a digital camera
(AxioCam) with the KS300 v 3.0 software (Carl Zeiss Microimaging,
Thornwood, New York). In addition to recorded images of sections
hybridized with sense and anti-sense probes, we also recorded
images away from the tissue to determine background probe
binding to the slide. To analyze each image for grain abundance, a
region in each image was circumscribed and a grain counting
Macro written for the KS300 imaging software (Zeiss) was used to
determine the total area, the percent area representing grains, and
the grain density for that image. For each experiment, usually two
slides per donor were hybridized with the anti-sense probe and 1
with the sense probe. Between four and six images were examined
at  630, recorded, and analyzed per slide.
Statistical analysis For each in situ hybridization experiment,
multiple images from young, middle-aged, and old donors were
analyzed for grain density and grains per cell of the circumscribed
dermal area of the image. After correcting for background
hybridization away from the tissue and from the sense strand
probe, we normalized each experiment to the lowest value, which
was given a value of 1. Data representing the relative grain density
per area and per cell from 35 donors ranging in age from 14 to 82
years were compared using ANOVA. Post hoc comparisons were
made using least significant difference (LSD) or the Tukey honest
significant difference (HSD) for unequal N tests. Microsoft Excel
(Excel 2000, Microsoft, Redmond, WA) and the Statistica (StatSoft,
v.5.5A; Statsoft, Tulsa, OK) software packages were used in these
analyses. All data in the bar graphs are reported as the mean
 standard deviation.
Tissue immunoﬂuorescence Prepared as described above,
slides containing 5 mm thick sections were removed from 801C,
air-dried and then fixed in cold methanol or in cold acetone for
2 min at 201C followed by 80% methanol at 41C for 5 min (M.
Detmar, personal communication). Tissue sections were blocked
(10% goat serum or donkey serum in PBS) and then incubated with
specified primary antibodies diluted in 10% serum in PBS
overnight at 41C. After washing sections, they were incubated
with the appropriate secondary antibody conjugated to either FITC
(fluorescein isothiocyanate) or Cy3 (Jackson ImmunoResearch
Labs; West Grove, Pennsylvania) for 1 h at RT in the dark.
Following incubation with the secondary antibody and washes,
coverslips were mounted with VECTASHIELD mounting medium
containing 40,6-diamidino-2-phenylindole (DAPI; Vector Labs,
Burlingame, California) to counterstain DNA and visualize the
nuclei of all cells. The following primary antibodies were used: a
rabbit polyclonal antibody to PEDF (BioProducts Maryland,
Middletown, Maryland), a mouse monoclonal anti-human CD31
to detect endothelial cells (R&D Systems; Minneapolis, Minnesota),
a rat monoclonal antibody to heparan sulfate proteoglycans to
detect basement membranes (Biomeda; Foster City, California), a
rabbit polyclonal antibody to Ki67 to detect proliferating cells
(Novocastra Laboratories, Newcastle-upon-Tyne, UK, Distributed
by US Vector Labs, Burlingame, CA), a chicken anti-human TSP-1
(thrombospondin, kindly provided by Robert Swerlick, Emory
University), a rabbit polyclonal antibody to TSP-2 (kindly provided
by Michael Detmar, Harvard Medical School/Massachusetts
General Hospital), and an affinity purified rabbit polyclonal anti-
body to VEGF (A-20, Santa Cruz Biotechnology; Santa Cruz,
California). In all experiments, secondary antibody alone served as
negative controls. Immunostained sections were examined at
 400 by fluorescence microscopy using a Zeiss microscope.
Images were captured as described above using a digital camera
with the AxioVision software (Carl Zeiss Microimaging).
MVD counts Cryostat sections (5 mm) were prepared as described
above and stained with an anti-human CD31 mouse monoclonal
antibody as described above to identify endothelial cells that line
blood vessels. Vessels were identified by fluorescence microscopy
using an FITC or Cy3 filter depending on the fluorophore-coupled
secondary antibody. Vessels were counted at 250  in five to eight
randomly selected fields per section. Five young and four old
donors were examined.
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